Trials / Unknown
UnknownNCT03541109
A Polypill for Secondary Prevention of Ischemic Heart Disease
Fixed Combination Therapy for Secondary Prevention of Major Cardiovascular Events
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,200 (estimated)
- Sponsor
- Isfahan University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. The most important aspect of CVD secondary prevention is adherence to guideline-indicated pharmacological therapy which globally remains low. In previous studies, a Polypill containing fixed dose combination of essential drugs have improved patient adherence to these drugs. The effect of such a strategy on pharmacological therapy uptake, cost-effectiveness, and CVD recurrence in our setting will be assessed in this study. Participants hospitalized in three referral hospitals in Isfahan, Iran because of an acute myocardial infarction (MI) (ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI)) will be randomized to either receiving Polypill or usual care after MI. Patient recruitment will be carried out at the time of patient discharge from the hospitals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Polypill | fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg) |
Timeline
- Start date
- 2019-05-20
- Primary completion
- 2023-08-01
- Completion
- 2024-08-01
- First posted
- 2018-05-30
- Last updated
- 2020-10-14
Locations
2 sites across 1 country: Iran
Source: ClinicalTrials.gov record NCT03541109. Inclusion in this directory is not an endorsement.